Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 1;11(1):2093054. doi: 10.1080/2162402X.2022.2093054

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — A modified oncolytic adenovirus successfully proliferates and produces IL15in tumor cells. (a) A schematic diagram of recombinant Ad-IL15. (b) The expression of IL-15. ELISA was used to measure IL-15 levels in the supernatant of cell cultures. Different human and mouse tumor cell lines were treated with Ad-IL15 for 24, 48, 72 or 96 h at the indicated dose (MOI = 50). The supernatant of untreated cell cultures was used as a control (CTR). (c) Cell proliferation analyses of Ad/Ad-IL15-infected human and mouse tumor cell lines. A CCK-8 assay was performed to evaluate the viability of different human and mouse cell lines treated with Ad/Ad-IL15 at different MOIs for 3 days. (d) Assessment of viral protein expression in three mouse cell lines infected with Ad-IL15 by western blotting.